{"filings":[{"id":128631,"accession_number":"0001193125-25-256604","cik":2029769,"company_name":"Oaktree Acquisition Corp. III Life Sciences","ticker":"OACC","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CFO Thomas Sweeney resigns; George Martinez appointed as new CFO at Oaktree Acquisition Corp. III Life Sciences","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Thomas Sweeney resigned as CFO effective Oct 29, 2025, to pursue other opportunities; no disagreement with Board or management.","Board appointed George A. Martinez as CFO effective immediately; Martinez is a Senior VP at Oaktree Capital Management, formerly Audit Senior Manager at EY.","Martinez will not receive compensation from the Company and has no employment agreement; he will enter into standard indemnity and letter agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":262543978.1525503,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128630,"accession_number":"0001193125-25-242643","cik":2029769,"company_name":"Oaktree Acquisition Corp. III Life Sciences","ticker":"OACC","form_type":"8-K","filed_at":"2025-10-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Oaktree Acquisition Corp. III Life Sciences appoints David A. Berry as independent director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Oct 17, 2025 as Class II director on audit, nominating, and compensation committees; deemed independent under Nasdaq and Rule 10A-3.","Co-founder & Managing Partner of Averin Capital (since May 2025); former Partner/GP at Flagship Pioneering (2005-2025); founder/CEO of Valo Health.","No cash compensation; eligible to invest non-controlling minority interest in Oaktree Acquisition Holdings III LS, consistent with other independent directors.","Will execute standard Letter Agreement and Indemnity Agreement on same terms as directors/officers from IPO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":262543978.1525503,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163795,"accession_number":"0001193125-25-137105","cik":2029769,"company_name":"Oaktree Acquisition Corp. III Life Sciences","ticker":"OACC","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Oaktree Acquisition Corp. III Life Sciences CFO resigns; Thomas Sweeney appointed CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Courtney Conigliaro resigned as CFO effective June 3, 2025; resignation not due to any disagreements.","Board appointed Thomas Sweeney as CFO (principal accounting/financial officer) effective June 3, 2025.","Sweeney is a Managing Director at Oaktree Capital Management; will not receive compensation from the company.","Board confirmed Alvin Shih as chair of the audit committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":262543978.1525503,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181672,"accession_number":"0001193125-25-002863","cik":2029769,"company_name":"Oaktree Acquisition Corp. III Life Sciences","ticker":"OACC","form_type":"8-K","filed_at":"2025-01-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Oaktree Acquisition Corp III board changes: Frank resigns, Kumar chairman, Pardesi appointed director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Frank resigned from the board effective Jan 6, 2025, not due to any disagreement with the company.","Aman Kumar, an existing director, was appointed as the new chairman of the board.","CEO Zaid Pardesi was appointed as a Class III director, term expiring at third annual shareholder meeting.","Pardesi and Kumar have material interests in the Sponsor Oaktree Acquisition Holdings III LS, as previously disclosed in the IPO prospectus.","No arrangements or family relationships exist between Pardesi and other directors or executive officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":262543978.1525503,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198455,"accession_number":"0001193125-24-274894","cik":2029769,"company_name":"Oaktree Acquisition Corp. III Life Sciences","ticker":"OACC","form_type":"8-K","filed_at":"2024-12-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oaktree Acquisition Corp. III Life Sciences units to separate into shares and warrants Dec 16","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Holders may elect to separate units into Class A ordinary shares and warrants starting December 16, 2024.","Separated shares trade under OACC, warrants under OACCW; units not separated continue under OACCU.","No fractional warrants will be issued; only whole warrants will trade.","Transfer agent Continental Stock Transfer & Trust will handle separation requests."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":262543978.1525503,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198454,"accession_number":"0001193125-24-251274","cik":2029769,"company_name":"Oaktree Acquisition Corp. III Life Sciences","ticker":"OACC","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"Oaktree Acquisition Corp. III Life Sciences closes partial over-allotment, trust grows to $192M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwriters purchased 1,699,029 additional units at $10.00 each, generating $16.99M gross proceeds.","Sponsor purchased 33,981 additional private placement units at $10.00 each for $339,810.","Sponsor forfeited 231,492 Class B ordinary shares at no cost as part of the over-allotment exercise.","Remaining 925,971 over-allotment units were forfeited by underwriters.","Total trust account now holds $191,990,290 from IPO, over-allotment, and private placement proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":262543978.1525503,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198453,"accession_number":"0001193125-24-248669","cik":2029769,"company_name":"Oaktree Acquisition Corp. III Life Sciences","ticker":"OACC","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oaktree Acquisition Corp. III Life Sciences completes $175M IPO, funds placed in trust for acquisition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed IPO of 17,500,000 units at $10.00 per unit, generating gross proceeds of $175,000,000.","Private placement of 550,000 units to sponsor at $10.00 per unit, gross proceeds $5,500,000.","Net proceeds $175,000,000 placed in trust account for benefit of public shareholders.","On Oct 30, partial over-allotment exercise: 1,699,029 units ($16,990,290); sponsor bought 33,981 private placement units ($339,810).","Audited balance sheet as of Oct 25, 2024 shows $177.1M total assets, $175M in trust, shareholders' deficit of $(5.5M)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":262543978.1525503,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198452,"accession_number":"0001193125-24-244185","cik":2029769,"company_name":"Oaktree Acquisition Corp. III Life Sciences","ticker":"OACC","form_type":"8-K","filed_at":"2024-10-25T23:59:59+00:00","items":["1.01","3.02","5.03","8.01","9.01"],"status":"ready","headline":"Oaktree Acquisition Corp. III Life Sciences prices $175M IPO at $10/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $175M from 17.5M units at $10.00 each; units trade on Nasdaq as OACCU.","Each unit comprises one Class A share and 1/5 redeemable warrant exercisable at $11.50.","Underwriters have 45-day over-allotment option for up to 2.625M additional units.","Sponsor purchased 550,000 private placement units at $10 each, generating $5.5M.","Net proceeds held in trust for initial business combination; 24-month deadline to complete."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":262543978.1525503,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}